2 'Moat-Worthy' Dividend Kings — Positive

FRT  GRC   Seeking Alpha — February 10, 2025

Dividend Kings are robust companies with competitive advantages, growing dividends for over 50 years, making them safe investments. Gorman-Rupp Company, with a strong product diversity and solid earnings, offers a 2% yield and a Strong Buy rating. Federal Realty, the only Dividend King REIT, boasts a resilient portfolio and a 4% dividend yield, with a Buy rating.

image for news 2 'Moat-Worthy' Dividend Kings

Super Micro Computer: Tomorrow Could Change Everything — Positive

SMCI   Seeking Alpha — February 10, 2025

On Friday, Super Micro Computer managed to record a higher high within its descending price trend, and now it really needs a fundamentally changing catalyst to keep going up. Despite margin pressures, SMCI's heavy R&D investments in the recent past and expanding data center solutions position it well in a growing market. SMCI's new manufacturing facilities in Malaysia and Silicon Valley should enhance production efficiency, potentially boosting margins and stock price.

image for news Super Micro Computer: Tomorrow Could Change Everything

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--monday.com Ltd. (NASDAQ: MNDY) (“monday.com”), the multi-product platform that runs all core aspects of work, today announced monday service is out of beta and available to all customers. As an AI-first Enterprise Service Management (ESM) platform, monday service empowers service teams across the entire organization to deliver exceptional support experiences faster. With smart automations that leverage the power of AI, monday service is a one-stop-s.

image for news monday.com Announces Full Release of monday service, its AI Enterprise Service Management Platform

monday.com Announces AI Vision to Empower Businesses to Scale — Neutral

MNDY   Business Wire — February 10, 2025

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--monday.com Ltd. (NASDAQ: MNDY) (“monday.com”), the multi-product platform that runs all core aspects of work, today announced its AI Vision, representing its key focus areas for 2025. Building on its robust platform, monday.com's strategy will focus on three pillars—AI Blocks, Product Power-ups, and the Digital Workforce—to accelerate its vision to democratize the power of software. monday.com's approach to AI aims to address the unique challenges b.

image for news monday.com Announces AI Vision to Empower Businesses to Scale

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer — Neutral

NCNA   Business Wire — February 10, 2025

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.

image for news Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.

image for news Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MGP Ingredients, Inc. ("MGP Ingredients" or "the Company") (NASDAQ:MGPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MGP Ingredients securities between May 3, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

image for news MGPI Stockholders Have Opportunity to Lead MGP Ingredients, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Streamlining the Referral Process to Enhance Efficiency and Patient Experience SOMERSET, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and AI-driven solutions, is proud to announce the launch of its new advanced referral module.

image for news Up to 70% Time Savings Achieved with Fully Integrated Advanced Referral Module of CareCloud's AI-Enabled EHR

Beamr CEO will Present a Keynote Speech at the ACM Mile-High-Video 2025 — Neutral

BMR   GlobeNewsWire — February 10, 2025

The Keynote Titled ״Is the future of video processing destined for GPU?״ Describes First Hand The Evolution of Video Encoding in the Past Decades Herzliya Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd.

image for news Beamr CEO will Present a Keynote Speech at the ACM Mile-High-Video 2025

McDONALD'S REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS — Neutral

MCD   PRNewsWire — February 10, 2025

Global Systemwide sales* were over $130 billion for the full year, with full year growth of more than $1 billion (more than $2 billion in constant currencies) Systemwide sales to loyalty members were approximately $30 billion for the full year and approximately $8 billion for the quarter across 60 loyalty markets, with full year growth of 30% over prior year 90-day active loyalty users were over 175 million across 60 loyalty markets as of year-end, with growth of approximately 15% over prior year CHICAGO , Feb. 10, 2025 /PRNewswire/ -- McDonald's Corporation today announced results for the fourth quarter and …

image for news McDONALD'S REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Glass Lewis Finds Matthews Has "Persistently Deteriorated and Consistently Underperformed During Substantially All Measurement Periods, Including During the Fullness of Mr. Bartolacci's Tenure as CEO" Asserts Barington "Has Offered Investors a Reasonable, Credible and Incremental Slate of Candidates" and a "More Promising Roadmap" for the Company Recommends Shareholders Vote "WITHHOLD" on Matthews' Nominees Terry L.

image for news Leading Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending Matthews International Shareholders Vote the GOLD Proxy Card "FOR" ALL of Barington Capital's Nominees: Ana Amicarella, Chan Galbato and James Mitarotonda

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ: NXT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nextracker securities between February 1, 2024 and August 1, 2024, both dates inclusive (the "Class Period").

image for news NXT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nextracker Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer — Neutral

IOVA   GlobeNewsWire — February 10, 2025

SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.

image for news Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Hydrofarm Announces Reverse Stock Split — Neutral

HYFM   GlobeNewsWire — February 10, 2025

SHOEMAKERSVILLE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (Nasdaq: HYFM) (“Hydrofarm” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on February 12, 2025. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on February 13, 2025, under the Company's existing trading symbol “HYFM.”

image for news Hydrofarm Announces Reverse Stock Split

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.

image for news Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Powerfleet Reports Third Quarter 2025 Financial Results — Neutral

AIOT   PRNewsWire — February 10, 2025

Q3 revenue rises to $106 million, an increase of 45% year-over-year, with service revenuerepresenting 77% of total revenue Adjusted EBITDA climbs to $22 million, an increase of 77%, driving an annual run ratesurpassing $85 million— doubling 2024 adjusted EBITDA FY25 full year guidance increased $10 million for revenue and $2.5 million for adjustedEBITDA Meaningful increase in adjusted gross margin performance, with total adjusted grossmargins now above 60%, and adjusted service gross margins approaching 70% Post-M&A integration ahead of schedule, priming for double digit growth trajectory in FY26 WOODCLIFF LAKE, N.J. , Feb. 10, 2025 /PRNewswire/ -- Powerfleet, Inc. (Nasdaq: AIOT) …

image for news Powerfleet Reports Third Quarter 2025 Financial Results

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").

image for news CRBU STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Orion Group Holdings Awarded $211.7 Million in New Contracts — Neutral

ORN   GlobeNewsWire — February 10, 2025

HOUSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”, “Orion”), a leading specialty construction company, today announced new Marine and Concrete awards for a total value of approximately $211.7 million. These projects are expected to begin in 2025 with varying completion dates extending through 2026. These awards further reinforce Orion's position as a leader in specialized Marine and Concrete construction.

image for news Orion Group Holdings Awarded $211.7 Million in New Contracts

PetMed Express: Dip Or Rip, A Buy After Earnings — Positive

PETS   Seeking Alpha — February 10, 2025

PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside.

image for news PetMed Express: Dip Or Rip, A Buy After Earnings

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.

image for news Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma